Skip to Content

Point Therapeutics Announces Preclinical Data Presentations at Upcoming American Association of Cancer Research Annual Meeting

BOSTON--(BUSINESS WIRE)--Apr 13, 2007 - Point Therapeutics, Inc. (NASDAQ: POTP) today reported the upcoming presentation of preclinical data at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) taking place in Los Angeles, California, April 14-18, 2007. The AACR poster presentations report on preclinical studies on talabostat's novel mechanism of action.

Additional details for the AACR presentations are as follows:

Presentation Date and Time: Monday, April 16, 2007, 8:00 AM -12:00 PM PT

Abstract #1894: Immune mechanisms of action of talabostat: a dipeptidyl peptidase targeted anti-tumor agent

Presentation Date and Time: Wednesday, April 18, 2007, 8:00 AM -12:00 PM PT

Abstract #5622: The anti-tumor potential of inhibitors of the DASH proteases in a mouse model of human breast cancer

The posters associated with the abstracts will be available on the Point Therapeutics' web site at immediately following their presentation.

About Point Therapeutics, Inc.:

Point is a Boston-based biopharmaceutical company currently studying its lead product candidate, talabostat, in two Phase 3 double blind, placebo-controlled trials in non-small cell lung cancer and in a Phase 2 trial in combination with gemcitabine in metastatic pancreatic cancer. Point has also studied talabostat in several Phase 2 trials, including as a single-agent in metastatic melanoma, in combination with cisplatin in metastatic melanoma and in combination with rituximab in advanced chronic lymphocytic leukemia.


Point Therapeutics, Inc.
Sarah Cavanaugh, 617-933-7508
Director, Corporate Communications

Posted: April 2007

View comments